| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 05/31/2007 | US20070123460 Probiotic compounds from Lactobacillus GG and uses therefor |
| 05/31/2007 | US20070123459 IL-17 like molecules and uses thereof |
| 05/31/2007 | US20070123458 homodimeric disintegrins as biodrugs; modulate the adhesion, motility, and invasiveness of integrin expressing tumor cells; anticoagulant, antitumor, and anticarcinogenic agents |
| 05/31/2007 | US20070123457 Carrier chimeric proteins, targeted carrier chimeric proteins and preparation thereof |
| 05/31/2007 | US20070123456 Novel regulator of endothelial cell function and vessel remodeling |
| 05/31/2007 | US20070123455 Immunomodulatory agents for treatment of inflammatory diseases |
| 05/31/2007 | US20070123454 Contact Inhibitory Factor (CIF) mediated inhibition of tumor metastasis and angiogenesis |
| 05/31/2007 | US20070123453 Uses of melanocortin-4 receptor (mc4r) agonist peptides administered by continuous infusion |
| 05/31/2007 | US20070123452 Method of selecting novel immunosuppressant |
| 05/31/2007 | US20070123451 Use of adiponectin to diagnose and treat malignancy |
| 05/31/2007 | US20070123450 oxidized glutathione-based compound having a stabilized disulfide bond and either platinum and palladium |
| 05/31/2007 | US20070123449 High load particles for inhalation having rapid release properties |
| 05/31/2007 | US20070123448 Novel chemical entities affecting neuroblastoma tumor-initiating cells |
| 05/31/2007 | US20070122884 Factor VII glycoforms |
| 05/31/2007 | US20070122883 Nucleotide sequences coding orphan receptor component of multimeric complex for use in identifying modulator for prevention and treatment of cell proliferative disorders |
| 05/31/2007 | US20070122866 Protein having PGE2 synthase activity and use thereof |
| 05/31/2007 | US20070122832 Process for Preparing L-amino Acids |
| 05/31/2007 | US20070122822 Compositions and methods for enhancing oligonucleotide-directed nucleic acid sequence alteration |
| 05/31/2007 | US20070122491 Methods and compositions for altering cell function |
| 05/31/2007 | US20070122490 Wound healing compound |
| 05/31/2007 | US20070122487 (Poly(acryloyl-hydroxyethyl starch)-plga composition microspheres |
| 05/31/2007 | US20070122486 Nanoparticulate insulin |
| 05/31/2007 | US20070122485 Organic compounds |
| 05/31/2007 | US20070122469 Method for producing a vesicle dispersion |
| 05/31/2007 | US20070122451 Biogically non-degradable peptides, angiostensin converting enzyme inhibitor, drug and functional food |
| 05/31/2007 | US20070122450 Treatment of ophthalmic conditions |
| 05/31/2007 | US20070122447 Shaped bodies and methods for their production and use |
| 05/31/2007 | US20070122446 Implants for treatment of symptomatic or degenerated intervertebral discs |
| 05/31/2007 | US20070122440 Methods for producing nanoparticles |
| 05/31/2007 | US20070122434 Heat shock genes and proteins from Neisseria meningitidis, Candida glabrata and Aspergillus fumigatus |
| 05/31/2007 | US20070122427 Delivery of trefoil peptides |
| 05/31/2007 | US20070122423 Derp1 and proderp1 allergen derivatives |
| 05/31/2007 | US20070122418 Compositions and methods for the pulmonary delivery of aerosolized medicaments |
| 05/31/2007 | US20070122414 Surface marker-directed cancer therapeutics |
| 05/31/2007 | US20070122412 Eg-vegf nucleic acids and polypeptides and methods of use |
| 05/31/2007 | US20070122410 Use of an active substance binding to CD28 for producing a pharmaceutical composition for the treatment of B-CLL |
| 05/31/2007 | US20070122409 Compounds, Compositions and Methods for the Endocytic Presentation of Immunosuppressive Factors |
| 05/31/2007 | US20070122403 Molecules with extended half-lives, compositions and uses thereof |
| 05/31/2007 | US20070122401 Methods and compositions for modulating telomerase reverse transcriptase (tert) expression |
| 05/31/2007 | US20070122400 Composition having liver function protecting effect |
| 05/31/2007 | US20070122399 Nutraceutical formulation for healing human bone due to accidental fracture or surgical replacement or grafting, containing lysine, proline, ascorbic acid, copper, and vitamin B6 |
| 05/31/2007 | US20070122396 Morphogenic proteins and stimulatory factors in gene therapy |
| 05/31/2007 | US20070122394 administering a VEGFR modulating agent that comprises placental growth factor; a growth factor that binds and activates Flt-1 such as PIGF or VEGF-B, an anti-Flt-1 agonistic antibody or a small molecule agonist |
| 05/31/2007 | US20070122384 Method for treating inflammatory bowel disease |
| 05/31/2007 | US20070122383 Interleukin-10 compositions for the treatment of adenocarcinomas |
| 05/31/2007 | US20070122382 Methods of treating cancer using il-21 and monoclonal antibody therapy |
| 05/31/2007 | US20070122381 Method for regulating neuron development and maintenance |
| 05/31/2007 | US20070122380 Chimeric cytokine of IL-7 and beta-chain of HGF and methods of use |
| 05/31/2007 | US20070122379 Combined tumor suppressor gene therapy and chemotherapy in the treatment of neoplasms |
| 05/31/2007 | US20070122378 Methods and compositions for the treatment of persistent infections |
| 05/31/2007 | US20070122377 Compositions and methods of treatment |
| 05/31/2007 | US20070122354 possess superior aerosol properties, even in the absence of stabilizing carriers or excipients; inhalants; when administered to the deep lung, are useful for treating allergic diseases, such as asthma, atopy, and atopic dermatitis |
| 05/31/2007 | DE102006012244A1 New 5-D-fructose dehydrogenase, optionally in combination with invertase, maltase and/or glucose isomerase, useful in therapy or diagnosis of disorders of fructose metabolism, including fructose intolerance |
| 05/31/2007 | DE102005056538A1 Composition, useful for e.g. preparing an agent for preventive, dermatological, therapeutic regenerative treatment of skin, comprises unmodified lipids, transferable proteins, non-transferable active substances and additives |
| 05/31/2007 | CA2631443A1 Potent compstatin analogs |
| 05/31/2007 | CA2631013A1 Activin-actriia antagonists and uses for promoting bone growth |
| 05/31/2007 | CA2630922A1 Treatment of neurodegenerative disorders |
| 05/31/2007 | CA2630586A1 Compositions and methods for treatment of diabetes |
| 05/31/2007 | CA2630404A1 Method for de-esterification of the lipopolysaccharide layer of neisseria meningitidis and mannheimia haemolytica |
| 05/31/2007 | CA2630216A1 Metabolite derivatives of the hdac inhibitor fk228 |
| 05/31/2007 | CA2630214A1 Methods to predict and prevent resistance to taxoid compounds |
| 05/31/2007 | CA2630147A1 Compositions for disrupting and inhibiting reconstitution of wound biofilm |
| 05/31/2007 | CA2630060A1 High-potency sweetener for weight management and compositions sweetened therewith |
| 05/31/2007 | CA2629569A1 Methods of treating cartilage defects |
| 05/31/2007 | CA2626933A1 Pharmaceutical composition |
| 05/30/2007 | EP1790728A2 Imaging, diagnosis and treatment of disease |
| 05/30/2007 | EP1790727A2 Proteins and nucleic acids encoding same |
| 05/30/2007 | EP1790726A2 Modified and stabilized GDF propeptides and uses thereof |
| 05/30/2007 | EP1790725A2 Proteins named after FCTRX and nucleic acids encoding same |
| 05/30/2007 | EP1790662A1 Nucleic acid and corresponding protein entitled 121P2A3 useful in treatment and detection of cancer |
| 05/30/2007 | EP1790660A2 Heterologous expression of neisserial proteins |
| 05/30/2007 | EP1790659A2 Polypeptides of pseudomonas aeruginosa |
| 05/30/2007 | EP1790658A2 Anti-viral vectors |
| 05/30/2007 | EP1790655A2 Biologically active peptides |
| 05/30/2007 | EP1790355A1 Propagation agent and propagation method for natural killer cell |
| 05/30/2007 | EP1790354A2 Use of plasminogen for promoting healing of tympanic membrane perforation |
| 05/30/2007 | EP1790353A1 Combined use of a GLP-1 compound and a modulator of diabetic late complications |
| 05/30/2007 | EP1790352A1 Use of botulinum toxin type B for the manufacture of a medicament for reducing pain associated with a muscle disorder |
| 05/30/2007 | EP1790351A1 Permucosal composition and method of improving permucosal absorption |
| 05/30/2007 | EP1790340A2 Combination chemotherapy |
| 05/30/2007 | EP1790334A2 Pharmacological inducement of the fed mode for enhanced drug administration to the stomach |
| 05/30/2007 | EP1789593A2 Soluble forms of hendra and nipah virus g glycoprotein |
| 05/30/2007 | EP1789552A2 Methods of regulating differentiation and treating of multiple myeloma |
| 05/30/2007 | EP1789449A1 Anti-glycated cd59 antibodies and uses thereof |
| 05/30/2007 | EP1789443A1 Muteins of fibroblast growth factor 21 |
| 05/30/2007 | EP1789442A2 Muteins of fibroblast growth factor 21 |
| 05/30/2007 | EP1789440A2 Pancreatic polypeptide family motifs and polypeptides comprising the same |
| 05/30/2007 | EP1789436A1 Antibacterial peptides and analogues thereof |
| 05/30/2007 | EP1789096A2 Aptamers to von willebrand factor and their use as thrombotic disease therapeutics |
| 05/30/2007 | EP1789078A1 Pulmonary delivery of a nerve agent neutralizing enzyme |
| 05/30/2007 | EP1789077A2 Methods for providing neuroprotection for the animal central nervous system against the effects of ischemia, neurodegeneration, trauma, and metal poisoning |
| 05/30/2007 | EP1789076A1 Methods of inducing melanogenesis in a subject. |
| 05/30/2007 | EP1789075A2 Absorption enhancers for drug administration |
| 05/30/2007 | EP1789074A2 Synthetic hyperglycosylated, protease-resistant polypeptide variants, oral formulations and methods of using the same |
| 05/30/2007 | EP1789073A1 Isolation of growth and differentiating factors from colostrum |
| 05/30/2007 | EP1789072A2 Prophylactic and therapeutic uses of fgf-20 in radiation protection |
| 05/30/2007 | EP1789070A2 Taj in neuronal function |
| 05/30/2007 | EP1789069A2 Cyclic peptides for treatment of cachexia |
| 05/30/2007 | EP1789068A2 Composition and method for prevention or treatment of stomatits |
| 05/30/2007 | EP1789067A2 Method of stimulating the motility of the gastrointestinal system using growth hormone secretagogues |